KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $75,388 | +2.5% | 12,062 | 0.0% | 0.00% | – |
Q4 2022 | $73,578 | -48.2% | 12,062 | +1.4% | 0.00% | – |
Q3 2022 | $142,133 | -8.0% | 11,894 | -2.9% | 0.00% | – |
Q2 2022 | $154,523 | +13.8% | 12,254 | +1.6% | 0.00% | – |
Q1 2022 | $135,773 | -47.6% | 12,058 | -17.6% | 0.00% | – |
Q4 2021 | $259,000 | -18.6% | 14,634 | +6.0% | 0.00% | – |
Q3 2021 | $318,000 | +34.7% | 13,805 | +82.5% | 0.00% | – |
Q1 2021 | $236,000 | – | 7,566 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |